Does the media refer more to NMTC or FONR?

In the previous week, Fonar had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 4 mentions for Fonar and 2 mentions for NeuroOne Medical Technologies. Fonar's average media sentiment score of 0.77 beat NeuroOne Medical Technologies' score of 0.00 indicating that Fonar is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fonar 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MBOT or NMTC?

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Microbot Medical. MarketBeat recorded 2 mentions for NeuroOne Medical Technologies and 1 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NYXH or NMTC?

In the previous week, Nyxoah had 4 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for Nyxoah and 2 mentions for NeuroOne Medical Technologies. Nyxoah's average media sentiment score of 0.19 beat NeuroOne Medical Technologies' score of 0.00 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroOne Medical Technologies (NMTC) Competitors

$3.46 +0.02 (+0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 -0.04 (-1.30%)

As of 04:10 PM Eastern

Compare

NMTC vs. FONR, MBOT, NYXH, INO, and VANI

Should you buy NeuroOne Medical Technologies stock or one of its competitors? MarketBeat compares NeuroOne Medical Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroOne Medical Technologies include Fonar (FONR), Microbot Medical (MBOT), Nyxoah (NYXH), Inovio Pharmaceuticals (INO), and Vivani Medical (VANI). These companies are all part of the "medical equipment" industry.

How does NeuroOne Medical Technologies compare to Fonar?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

NeuroOne Medical Technologies currently has a consensus target price of $11.67, suggesting a potential upside of 237.19%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fonar has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.46	-$3.61M	-$0.85	N/A
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

NeuroOne Medical Technologies has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Fonar has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, Fonar had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 4 mentions for Fonar and 2 mentions for NeuroOne Medical Technologies. Fonar's average media sentiment score of 0.77 beat NeuroOne Medical Technologies' score of 0.00 indicating that Fonar is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fonar	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 7.9% of Fonar shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fonar has a net margin of 6.35% compared to NeuroOne Medical Technologies' net margin of -68.35%. Fonar's return on equity of 4.12% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%
Fonar	6.35%	4.12%	3.07%

Summary

Fonar beats NeuroOne Medical Technologies on 11 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Microbot Medical currently has a consensus price target of $6.63, indicating a potential upside of 264.01%. NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 237.19%. Given Microbot Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

NeuroOne Medical Technologies has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
NeuroOne Medical Technologies	$12.10M	2.46	-$3.61M	-$0.85	N/A

Microbot Medical has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. Microbot Medical's return on equity of -21.84% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Microbot Medical. MarketBeat recorded 2 mentions for NeuroOne Medical Technologies and 1 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Microbot Medical beats NeuroOne Medical Technologies on 9 of the 15 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

NeuroOne Medical Technologies has higher revenue and earnings than Nyxoah. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.76	-$101.92M	-$2.48	N/A
NeuroOne Medical Technologies	$12.10M	2.46	-$3.61M	-$0.85	N/A

In the previous week, Nyxoah had 4 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for Nyxoah and 2 mentions for NeuroOne Medical Technologies. Nyxoah's average media sentiment score of 0.19 beat NeuroOne Medical Technologies' score of 0.00 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Nyxoah presently has a consensus price target of $7.67, suggesting a potential upside of 451.56%. NeuroOne Medical Technologies has a consensus price target of $11.67, suggesting a potential upside of 237.19%. Given Nyxoah's higher possible upside, equities analysts clearly believe Nyxoah is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Nyxoah's net margin of -543.21%. NeuroOne Medical Technologies' return on equity of -98.33% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

Summary

NeuroOne Medical Technologies beats Nyxoah on 10 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Inovio Pharmaceuticals has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -98.33% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

Inovio Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Inovio Pharmaceuticals presently has a consensus target price of $4.25, suggesting a potential upside of 289.91%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 237.19%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeuroOne Medical Technologies has higher revenue and earnings than Inovio Pharmaceuticals. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,494.57	-$84.95M	-$1.45	N/A
NeuroOne Medical Technologies	$12.10M	2.46	-$3.61M	-$0.85	N/A

In the previous week, Inovio Pharmaceuticals had 10 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 12 mentions for Inovio Pharmaceuticals and 2 mentions for NeuroOne Medical Technologies. Inovio Pharmaceuticals' average media sentiment score of 0.60 beat NeuroOne Medical Technologies' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats NeuroOne Medical Technologies on 10 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Vivani Medical has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -98.33% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

Vivani Medical presently has a consensus target price of $3.50, indicating a potential upside of 204.35%. NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 237.19%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vivani Medical has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

In the previous week, NeuroOne Medical Technologies had 2 more articles in the media than Vivani Medical. MarketBeat recorded 2 mentions for NeuroOne Medical Technologies and 0 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score.

Company	Overall Sentiment
Vivani Medical	Neutral
NeuroOne Medical Technologies	Neutral

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has higher revenue and earnings than Vivani Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
NeuroOne Medical Technologies	$12.10M	2.46	-$3.61M	-$0.85	N/A

Summary

NeuroOne Medical Technologies beats Vivani Medical on 9 of the 14 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTC vs. The Competition

Export

Metric	NeuroOne Medical Technologies	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.65M	$8.69B	$6.49B	$11.99B
Dividend Yield	N/A	1.76%	2.67%	5.58%
P/E Ratio	-4.07	22.81	23.92	23.74
Price / Sales	2.46	18.98	507.55	107.95
Price / Cash	N/A	12.81	26.99	37.25
Price / Book	4.07	5.21	10.28	6.78
Net Income	-$3.61M	$177.20M	$3.57B	$337.51M
7 Day Performance	-6.99%	-2.49%	-1.43%	-2.72%
1 Month Performance	-27.31%	5.28%	3.27%	1.87%
1 Year Performance	-0.87%	2.31%	23.37%	26.60%

NeuroOne Medical Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTC NeuroOne Medical Technologies	1.9915 of 5 stars	$3.46 +0.6%	$11.67 +237.2%	-1.4%	$29.65M	$12.10M	N/A	20	News Coverage
FONR Fonar	2.9814 of 5 stars	$18.91 +0.1%	N/A	N/A	$116.64M	$104.35M	18.91	480
MBOT Microbot Medical	2.1634 of 5 stars	$1.81 +5.8%	$7.50 +314.4%	-34.5%	$114.85M	N/A	N/A	20	Gap Up
NYXH Nyxoah	3.232 of 5 stars	$2.70 -5.9%	$7.67 +184.0%	-81.1%	$111.24M	$11.33M	N/A	110	Gap Up
INO Inovio Pharmaceuticals	2.6551 of 5 stars	$1.26 -6.7%	$4.50 +257.1%	-52.9%	$111.07M	$60K	N/A	320	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. FONR, MBOT, NYXH, INO, and VANI

How does NeuroOne Medical Technologies compare to Fonar?

Summary

How does NeuroOne Medical Technologies compare to Microbot Medical?

Summary

How does NeuroOne Medical Technologies compare to Nyxoah?

Summary

How does NeuroOne Medical Technologies compare to Inovio Pharmaceuticals?

Summary

How does NeuroOne Medical Technologies compare to Vivani Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. FONR, MBOT, NYXH, INO, and VANI

How does NeuroOne Medical Technologies compare to Fonar?

Do analysts rate NMTC or FONR?

Which has stronger valuation & earnings, NMTC or FONR?

Which has more volatility and risk, NMTC or FONR?

Does the media refer more to NMTC or FONR?

Do institutionals and insiders have more ownership in NMTC or FONR?

Is NMTC or FONR more profitable?

Summary

How does NeuroOne Medical Technologies compare to Microbot Medical?

Do analysts prefer MBOT or NMTC?

Which has more volatility and risk, MBOT or NMTC?

Which has preferable valuation and earnings, MBOT or NMTC?

Is MBOT or NMTC more profitable?

Do insiders & institutionals hold more shares of MBOT or NMTC?

Does the media prefer MBOT or NMTC?

Summary

How does NeuroOne Medical Technologies compare to Nyxoah?

Which has stronger earnings & valuation, NYXH or NMTC?

Does the media favor NYXH or NMTC?

Which has more volatility & risk, NYXH or NMTC?

Do analysts prefer NYXH or NMTC?

Do insiders and institutionals have more ownership in NYXH or NMTC?

Is NYXH or NMTC more profitable?

Summary

How does NeuroOne Medical Technologies compare to Inovio Pharmaceuticals?

Is INO or NMTC more profitable?

Which has more volatility & risk, INO or NMTC?

Do analysts recommend INO or NMTC?

Do insiders & institutionals hold more shares of INO or NMTC?

Which has stronger valuation and earnings, INO or NMTC?

Does the media prefer INO or NMTC?

Summary

How does NeuroOne Medical Technologies compare to Vivani Medical?

Is VANI or NMTC more profitable?

Do analysts recommend VANI or NMTC?

Which has more volatility and risk, VANI or NMTC?

Does the media prefer VANI or NMTC?

Do institutionals and insiders have more ownership in VANI or NMTC?

Which has preferable valuation & earnings, VANI or NMTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools